Breaking News, Financial News

Financial Report: PDL BioPharma

Revenues up 18% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PDL BioPharma 4Q Revenues: $86.0 million (+18%) 4Q Earnings: $49.4 million (+27%) FY Revenues: $374.5 million (+3%) FY Earnings: $211.7 million (+6%) Comments: Growth in the quarter was primarily driven by increased royalties from sales of Herceptin and Avastin, which are marketed by Genentech and Roche. Royalty revenues for the year were up 7%....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters